ModernaMRNA
Recorded

Moderna Investor Day 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration3 hr 53 min

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Speaker

Good morning. Thank you so much for being with us this morning. We are very happy with the team to welcome those of you in the room in Marlborough, the site for intismeran. Thank you so much for joining us also online. We will be making forward-looking statements today, and investing in Moderna entails risk, so please look at the forward-looking statements on the SEC website, on the company website. As you know, mRNA is nature's information molecule, carrying instructions to make protein in every living organism on the planet. Moderna was founded on the idea that if we could find a way to use mRNA, we could make new medicines for patients that not only secreted protein, but also transmembrane protein, and also go inside the cells' compartments. What is very interesting about mRNA is biology uses four letters to code every protein in life.

Speaker

mRNA is really an instructions molecule. Because of that very unique feature of mRNA as an instruction molecule, as an information molecule, we thought that if we could invest in basic mRNA science, if we could invest in delivery system science, if we could invest in manufacturing and technical development, we would be able to build a set of bricks, technology bricks, like a Lego, that then you can put together to make medicine. We could, maybe for the first time in the history of this industry, build a true platform where you can learn from one medicine to another one, when you can go faster from one medicine to another one. That was kind of how we set up the company from the beginning. Pretty quickly, we decided to use a concept of modalities.

Speaker

A modality is a set of medicines that use exactly all the same technology bricks, the same chemistry in the mRNA, the same technology mRNA, the same delivery system, the same lipid, the same manufacturing processes. That feature of standardization, which is used in many other industries, but not really in pharmaceuticals, is a very powerful feature because you learn once, and then you scale. If you think about the modalities, think about the vaccine as the modality number 1, if you want, on the left. Getting to the first vaccine was a long journey. Then getting the second, the third, the fourth vaccines is a much more scalable process, which is why we were able to move so quickly during COVID, because this was not our first vaccine. We had done nine vaccines in clinical studies before.

Speaker

We had developed the platform, the manufacturing processes, the technology. This is how we think about the company. If you think about the unique properties of mRNA to make those protein secreted on the cell membrane intracellular, this is over time, and I am not talking months, I am talking years and decades, this is a very, very large product opportunity. Because most of the genes coding proteins in our DNA are coding for proteins that are not secreted, that are actually not addressable by the recombinant technologies. The other piece is if you have the modality approach, the standardization of medicines, chemistry, manufacturing processes, you should over time have a higher efficiency in R&D, a higher probability of technical success of medicines, because it is not like every time you put a new chemical in a human body when you go into the clinic.

Speaker

For each modality, it is the same chemical that you put in the human body as the previous one. You just change the order of the letters. But from a chemical standpoint, from a pharm/tox standpoint, it is the same chemical. The other piece, of course, is with a platform, if you standardize, if you invest in IT, if you invest in robotics, you can develop drugs rapidly. Because again, unlike in pharmaceutical, where every medicine is a different chemical, you do not have to reinvent the manufacturing process for every drug. You do not have to build a plant for every drug, which is the last piece of a puzzle, which is greater capital efficiency. Again, like any platform, and we can look at the technology industry to look at what platform companies have done, to invest in a platform takes time and a lot of capital.

Speaker

When you have a platform built in science, in manufacturing, you can scale the platform at a pace and at a capital efficiency that is very, very different. That's the vision we had. So where are we today? As you know, we have three established modalities, infectious disease vaccine, individual cancer treatment, and rare genetic liver diseases. We try to always use the mRNA technology not to do me-too products. We could in theory do another GLP-1 mRNA, but we don't think what this will bring in term of new value to patients and to the world. We want to use the technology to try to think about what other things we can do for patients that will over time create value for shareholders, but what we can do for patients that is different and could have an impact.

Speaker

If you think about those three modalities, they're quite interesting because we think they're going to have a very durable franchise. If you look at infectious disease vaccine, there's not a lot of vaccine players. One of the reason, as you know, is you need to run very large phase III in vaccine. There are 700, 800 billion dollars, so it's a pretty big barrier to entry. There's no generics in vaccine. You have to prove back again to the regulator because of the safety element that not only the vaccine is working, but it's safe. So it's pretty high barrier to entry in infectious disease. For intismeran, what's going to be really interesting, because as you know, those are individualized medicines by design, the algorithm, I will talk about it more, is ours. It's not public, it's not patented. The algorithm is ours. We think that's going to be an interesting limitation to generics for the intismeran franchise.

Speaker

As you all know, rare genetic disease, it is very, very difficult to run a clinical study if you have a new drug, if there's a drug approved for those children, because you have to convince the parents and the doctors that it's the right thing to do for the children to take them out of a drug working to a drug that is experimental, that the safety profile, the efficacy of that new drug is not known. So we think also in rare genetic disease, we're going to have a very durable franchise.

Speaker

If you think about how we're trying to build this platform company, because it's kind of a unique way to build a biopharma platform company, we are trying to think about how we invest for growth in the near term, but how we not lose sight of what we can do for patients in five or 10 or 15 years, but what we do in the labs today. We try to think about different time horizons. Horizon one is really established modality, the three modalities I spoke about, infectious disease vaccines, intismeran, rare genetic disease. Horizon two, we spoke about it quite a lot at Science Day a few months ago. It's really new modalities that we are trying to get proof of concept in the clinic that are in phase I or phase II.

Speaker

One that comes to mind, because of the press release, I think last week, is mRNA-2808, our T-cell engager for multiple myeloma. That is basically the first medicine, the sentinel medicine in the T-cell engager modality of Moderna. We think that modality is really interesting compared to what you can do with recombinant, because you can multiplex that product at three T-cell engagers, and we could do more as the biology requires. Horizon three are modalities that are preclinical, but where the team is working really hard to finalize all the pieces to take those modalities into the clinic. One that comes to mind that we also talked about at Science Day in June is the in vivo CAR-T. It's not in the clinic yet, but it's going to be in the clinic very, very soon.

Speaker

Those are basically programs that the team in the labs is working on to put the technology bricks together in a new way, sometime with new technology bricks, to build not one new medicine, but a whole family of new medicines. That's for horizon three. Horizon four is basically inventing new mRNA technology blocks. What we're doing for horizon four is investing a lot in what we can do and accelerate our learnings through AI. We presented at Science Day in June, LUCY, which is basically an AI-enabled full system that generates scientific hypotheses through AI, that basically instructs robots to make the mRNA, to make the lipid. Then those are tested in robots as well in vitro, then in animal model, and then you feed back the data into a system and you keep learning.

Speaker

This is very proprietary data, obviously, and it's totally changing the pace at which we are learning as a company. The team is really very focused on how to use LUCY, how to improve LUCY, and this has really become a key part of our company advantage in terms of mRNA technology. Which is quite interesting when you think about where we are today, and I'll talk about it in my close, in terms of how the mRNA industry has changed just in the last few years. Of course, we also AI across the company. We've talked about it in previous investor days. We've had several sessions about it.

Speaker

We think it's a very, very interesting opportunity for us to transform the company, to reinvent the company, in terms of how do we improve quality, how do we improve speed, how do we improve scalability, and how do we also get cost savings through a process. We really think that if you can improve quality across everything we do, if you can increase speed and reduce time, think just about clinical trial development, filing a BLA, manufacturing approval of products, all these timelines. If you can compress time, you can create a lot of value. As Juan will talk about later in terms of just the capacity of Marlborough, as you reduce cycle time, you not only provide the medicine faster for patients, but also you increase your capacity.

Speaker

Speed is a very important element, and scalability when you have a platform is fundamental to be able to scale more medicine without having more complexity as you build the company. We have a very exciting morning planned for you. Stephen is going to come now to talk about the business strategy of our company. Then we'll have Juan talking about manufacturing. Jamie will come and close the business section with financials and financial frameworks. Then we have a Q&A with that group to answer more business questions. After a coffee break, we'll have Rita and Bill talking to you about infectious disease. Then David will talk about his favorite topic, which is intismeran and oncology.

Speaker

I'll come back to close with just a couple of slides, and then we'll take those of you that are in the room, we'll take you on a tour. That's why you came to Marlborough. Thanks for making the trip. It's a bit out of Boston and away from Logan, but I think you'll get a good sense of how different this technology is from CAR-T. I've read in many, many notes, this is going to be like CAR-T. I hope after the visit, you have a good sense that it's nothing to do with CAR-T. The only commonality with CAR-T is it's individualized. That is the end of it. Have a great morning, and with this, I pass to my partner, Stephen.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day